1,1-dimethylethyl [(1S)-3-hydroxy-1-(phenylmethyl)propyl]carbamate | 94670-70-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl [(1S)-3-hydroxy-1-(phenylmethyl)propyl]carbamate
• 英文别名: 3-<(tert-butoxycarbonyl)amino>-4-phenyl-1-butanol；tert-butyl N-[(1S)-1-benzyl-3-hydroxy-propyl]carbamate；(S)-tert-butyl-4-hydroxy-1-phenylbutan-2-ylcarbamate；N-[(1S)-3-hydroxy-1-benzylpropyl](tert-butoxy)carboxamide；3-[(tert-butoxycarbonyl)amino]-4-phenyl-1-butanol；tert-butyl N-[(2S)-4-hydroxy-1-phenylbutan-2-yl]carbamate
• CAS: 94670-70-9
• 化学式: C₁₅H₂₃NO₃
• 分子量: 265.353
• InChiKey: VTFUOCMRCJLSLL-CYBMUJFWSA-N

物化性质

• 熔点：
  55-57 °C
• 沸点：
  422.3±45.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl [(1S)-3-hydroxy-1-(phenylmethyl)propyl]carbamate 在 三氧化硫吡啶 、 二甲基亚砜 、 三乙胺 、 水 作用下， 反应 0.17h， 生成 3-[(tert-butoxycarbonyl)amino]-4-phenylbutanaldehyde
  参考文献：
  名称：

  INHIBITORS OF CYTOCHROME P450

  摘要：

  公开号：

  EP2231628B1
• 作为产物：
  描述：

  ((S)-1-benzylallyl)carbamic acid tert-butyl ester 在 sodium hydroxide 、 9-borabicyclo[3.3.1]nonane dimer 、 双氧水 作用下， 生成 1,1-dimethylethyl [(1S)-3-hydroxy-1-(phenylmethyl)propyl]carbamate
  参考文献：
  名称：

  Amino Diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR

  摘要：

  A series of HIV protease inhibitors containing a novel C-2 symmetrical ''aminodiol'' core structure were prepared from amino acid starting materials. The ability of the aminodiols to inhibit HIV replication in cell culture is comparable to their ability to inhibit the isolated enzyme, a result compatible with good cell membrane penetration by this class of compounds. Optimization of the structure-activity in this series led to aminodiol 9a (K-i = 100 nM; ED(50) (HIV-1) = 80 nM) containing P-1/P-1', benzyl and P-2/P-2' Boc substituents. Compound 9a is a selective inhibitor of HIV protease versus other aspartyl proteases such as human renin, human cathepsin D, and porcine pepsin. In addition, 9a is equipotent against HIV-1 and HIV-2 in cell culture and demonstrates similar activity in infected T-lymphocytes and PBMCs. After iv and oral administration in rats, 9a displayed significant oral bioavailability (ca. 40%) and a promising plasma elimination half-life (4 h).

  DOI：

  10.1021/jm00038a005

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• [EN] SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS<br/>[FR] DÉRIVÉS D'AZÉTIDINE SUBSTITUÉS EN TANT QUE LIGANDS DE TAAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016030310A1

  公开（公告）日：2016-03-03

  The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is hydrogen or fluoro; L1 is -CH2-, -NR'-, -0-, -S-, CF2- or CH=; R' is hydrogen or lower alkyl; L2 is a bond, -C(0)NH-, -NH-, -CH2NHC(O)-, -NHC(O)- or -NHC(0)NH-; R is hydrogen, halogen, lower alkoxy, cyano or is phenyl optionally substituted by one or more substituents, selected from halogen, lower alkyl substituted by halogen or lower alkoxy, or is a five or six membered heteroaryl, selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or pyrazolyl, which heteroaryls are optionally substituted by one or more substituents, selected from halogen, lower alkyl, lower alkoxy, cyano, cycloalkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or by phenyl substituted by halogen; N is a ring nitrogen atom in position 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及一种具有以下式I的化合物，其中R1是氢、甲氧基或氟；R2/R2'分别独立地是氢、甲氧基或氟；R3/R4分别独立地是氢或卤素；R是氢或氟；L1是-CH2-、-NR'-、-O-、-S-、CF2-或CH=；R'是氢或较低的烷基；L2是键、-C(0)NH-、-NH-、-CH2NHC(O)-、-NHC(O)-或-NHC(0)NH-；R是氢、卤素、较低的烷氧基、氰基或是苯环，可以选择性地被一个或多个取代基取代，所述取代基选自卤素、被卤素或较低的烷氧基取代的较低烷基、或是被卤素取代的苯环，或是一个五元或六元杂环芳基，选自吡啶基、嘧啶基、吡嗪基、吡啶嗪基或吡唑基，这些杂环芳基可以选择性地被一个或多个取代基取代，所述取代基选自卤素、较低的烷基、较低的烷氧基、氰基、环烷基、被卤素取代的较低烷基、被卤素取代的较低烷氧基或被卤素取代的苯基；N是1或2位置的环氮原子；或其药学上适宜的酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力，特别是对TAAR1，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍(ADHD)、与压力有关的障碍、如精神分裂症、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyltripeptide analogs of enalapril
  作者：William J. Greenlee、Patricia L. Allibone、Debra S. Perlow、Arthur A. Patchett、Edgar H. Ulm、Theodore C. Vassil

  DOI：10.1021/jm00382a008

  日期：1985.4

  The synthesis and biological activity of a series of inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) are described. Incorporation of the substituted N-carboxymethyl dipeptide design of enalapril (MK-421) into acyl tripeptides and larger peptides yielded potent inhibitors of the enzyme. These can be viewed as substrate analogues in which the carbonyl of the scissile peptide bond is replaced

  描述了一系列血管紧张素转化酶抑制剂的合成和生物学活性（EC 3.4.15.1）。依那普利的取代N-羧甲基二肽设计（MK-421）并入酰基三肽和较大的肽中，产生了该酶的强效抑制剂。这些可以看作是底物类似物，其中易裂肽键的羰基被CHCO2H基团取代。所描述的几种类似物具有与依那普利拉（MK-422）相同的抑制能力，但是没有一个能实现增强的效力，这将证明肽链的延长引起了额外的结合相互作用。所描述的设计的应用对于抑制其他金属肽酶可能是有用的。
• Module Assembly for Protein-Surface Recognition: Geranylgeranyltransferase I Bivalent Inhibitors for Simultaneous Targeting of Interior and Exterior Protein Surfaces
  作者：Shinnosuke Machida、Kakeru Usuba、Michelle A. Blaskovich、Akiko Yano、Kazuo Harada、Saïd M. Sebti、Nobuo Kato、Junko Ohkanda

  DOI：10.1002/chem.200701634

  日期：2008.2.8

  probes designed to simultaneously targeting multiple sites of protein surfaces are of interest owing to their potential application as site specific modulators of protein-protein interactions. A new approach toward bivalent inhibitors of mammalian type I geranylgeranyltransferase (GGTase I) based on module assembly for simultaneous recognition of both interior and exterior protein surfaces is reported. The

  设计用于同时靶向蛋白质表面多个位点的合成化学探针由于其作为蛋白质-蛋白质相互作用的位点特异性调节剂的潜在应用而受到关注。报道了一种基于模块组装同时识别内部和外部蛋白质表面的针对哺乳动物I型香叶基香叶基转移酶（GGTase I）的二价抑制剂的新方法。在这项研究中合成的抑制剂由通过烷基间隔基连接的两个模块组成。一个是四肽CVIL模块，用于与内部蛋白质表面（活性口袋）结合，另一个是3,4,5-烷氧基取代的苯甲酰基基序，其中包含三个氨基烷基，旨在与活性区域附近的带负电荷的蛋白质外表面结合地点。通过基于荧光光谱法的两种不同的酶抑制试验以及将[（3H）]标记的异戊二烯基结合到蛋白质底物上来筛选化合物。二价抑制剂以亚微摩尔范围的K（i）值阻断GGTase I的酶促活性，分别比四肽CVIL和苯甲酸甲酯衍生物高一个数量级，并且效力高出150倍以上。二价化合物6和8被证明是竞争性抑制剂，表明CVIL模块将整个分子锚定在GGTase
• Copper-Catalyzed Borylation of Cyclic Sulfamidates: Access to Enantiomerically Pure (β-and γ-Amino­alkyl)boronic Esters
  作者：Nina Ursinyova、Robin B. Bedford、Timothy Gallagher

  DOI：10.1002/ejoc.201501492

  日期：2016.2

  Abstract Cyclic sulfamidates undergo borylation under copper‐catalyzed conditions using B2pin2 to give enantiomerically (and diasteromerically) defined (aminoalkyl)boronic esters. External iodide is essential, but the intermediacy of simple alkyl iodides has been excluded; N‐sulfated intermediates are key in the borylation sequence. Based on stereochemical studies and trapping experiments, the involvement

  摘要 环状磺酰胺在铜催化条件下使用 B2pin2 进行硼酸化，得到对映异构（和非对映异构）定义的（氨基烷基）硼酸酯。外部碘化物是必不可少的，但简单的烷基碘化物已被排除在外；N-硫酸化中间体是硼酸化序列中的关键。基于立体化学研究和捕获实验，在这些铜催化条件下碳中心自由基的参与似乎是可能的。